José Antonio Nieto

José Antonio Nieto


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2013 in Thrombosis Research
Verified
Journal Article
Open access
PDF file
JNJosé Antonio Nieto
José Antonio Nieto
RSRosario Solano
Rosario Solano
NINatacha Trapero Iglesias
Natacha Trapero Iglesias
NRNuria Ruiz-Giménez
Nuria Ruiz-Giménez
CFCarmen Fernández-Capitán
Carmen Fernández-Capitán
MMManuel Monreal
Manuel Monreal
Venous thromboembolism (VTE) is a commonly diagnosed condition with significant morbidity and mortality [ 1 x [1] Kearon, C., Akl, E.A., Comerota, A.J., Prandoni, P., Bounameaux, H., Goldhaber, S.Z. et al. Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis (9th Edition): American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: e419S–e494S ([Suppl.]) Crossref | PubMed | Scopus (1996) | Google Scholar See all References ] [1] . Current guidelines recommend patients with VTE to be initially treated with low-molecular-weight heparin (LMWH), unfractionated heparin or fondaparinux, followed by long-term anticoagulation, which is usually accomplished with vitamin K antagonists (VKA) [ 2 x [2] Lagerstedt, C.I., Olsson, C.G., Fagher, B.O., Oqvist, B.W., and Albrechtsson, U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985; : 515–518 Abstract | PubMed | Scopus (459) | Google Scholar See all References , 3 x [3] Hull, R., Delmore, T., Genton, E., Hirsh, J., Gent, M., Sackett, D. et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979; 301: 855–858 Crossref | PubMed | Scopus (475) | Google Scholar See all References ]. Recommendations for long-term therapy are based on randomized clinical trials [ 2 x [2] Lagerstedt, C.I., Olsson, C.G., Fagher, B.O., Oqvist, B.W., and Albrechtsson, U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985; : 515–518 Abstract | PubMed | Scopus (459) | Google Scholar See all References , 3 x [3] Hull, R., Delmore, T., Genton, E., Hirsh, J., Gent, M., Sackett, D. et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979; 301: 855–858 Crossref | PubMed | Scopus (475) | Google Scholar See all References , 4 x [4] Levine, M.N., Hirsh, J., Gent, M., Turpie, A.G., Weitz, J., Ginsberg, J. et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995; 74: 606–611 PubMed | Google Scholar See all References , 5 x [5] Kearon, C., Ginsberg, J.S., Kovacs, M.J., Anderson, D.R., Wells, P., Julian, J.A. et al. Extended Low-Intensity Anticoagulation for Thromboembolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thrombo-embolism. N Engl J Med. 2003; 349: 631–639 Crossref | PubMed | Scopus (663) | Google Scholar See all References , 6 x [6] Ridker, P.M., Goldhaber, S.Z., Danielson, E., Rosenberg, Y., Eby, C.S., Deitcher, S.R. et al. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 348: 1425–1434 Crossref | PubMed | Scopus (721) | Google Scholar See all References , 7 x [7] Schulman, S., Rhedin, A.S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995; 332: 1661–1665 Crossref | PubMed | Scopus (883) | Google Scholar See all References , 8 x [8] Agnelli, G., Prandoni, P., Santamaria, M.G., Bagatella, P., Iorio, A., Bazzan, M. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin optimal Duration Italian Trial Investigators. N Engl J Med. 2001; 345: 165–169 Crossref | PubMed | Scopus (520) | Google Scholar See all References , 9 x [9] Pinede, L., Ninet, J., Duhaut, P., Chabaud, S., Demolombe-Rague, S., Durieu, I. et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf vein thrombosis. Circulation. 2001; 103: 2453–2460 Crossref | PubMed | Scopus (352) | Google Scholar See all References , 10 x [10] Agnelli, G., Prandoni, P., Becattini, C., Silingardi, M., Taliani, M.R., Miccio, M. et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003; 139: 19–25 Crossref | PubMed | Scopus (297) | Google Scholar See all References ] that assessed relevant outcomes like VTE recurrences and major bleeding rates, because most trials were underpowered to assess fatal VTE or fatal bleeding events. Furthermore, a number of patients are often excluded from randomized trials of anticoagulation because of co-morbid conditions, short life expectancy, pregnancy or contraindications to therapy, which means that treatment regimens based on the results from randomized clinical trials might not be generalisable to all patients with VTE.

21 March 2023 in British Journal of Haematology
Verified
Journal Article
Open access
DMDamián Mora
Damián Mora
JMJorge Mateo
Jorge Mateo
JNJosé Antonio Nieto
José Antonio Nieto
BBBehnood Bikdeli
Behnood Bikdeli
YYYugo Yamashita
Yugo Yamashita
TIthe Registro Informatizado de Enfermedad TromboEmbólica (RIETE) Investigators
the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) Investigators
Summary: Predictive tools for major bleeding (MB) using machine learning (ML) might be advantageous over traditional methods. We used data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) to develop ML algorithms to identify patients with venous thromboembolism (VTE) at increased risk of MB during the first 3 months of anticoagulation. A total of 55 baseline variables were used as predictors. New data prospectively collected from the RIETE were used for further validation. The RIETE and VTE‐BLEED scores were used for comparisons. External validation was performed with the COMMAND‐VTE database. Learning was carried out with data from 49 587 patients, of whom 873 (1.8%) had MB. The best performing ML method was XGBoost. In the prospective validation cohort the sensitivity, specificity, positive predictive value and F1 score were: 33.2%, 93%, 10%, and 15.4% respectively. F1 value for the RIETE and VTE‐BLEED scores were 8.6% and 6.4% respectively. In the external validation cohort the metrics were 10.3%, 87.6%, 3.5% and 5.2% respectively. In that cohort, the F1 value for the RIETE score was 17.3% and for the VTE‐BLEED score 9.75%. The performance of the XGBoost algorithm was better than that from the RIETE and VTE‐BLEED scores only in the prospective validation cohort, but not in the external validation cohort.

9 June 2021 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
DMDamian Mora
Damian Mora
JNJosé Antonio Nieto
José Antonio Nieto
JMJorge Mateo
Jorge Mateo
BBBehnood Bikdeli
Behnood Bikdeli
SBStefano Barco
Stefano Barco
MMManuel Monreal
Manuel Monreal
Background Patients with pulmonary embolism (PE) who prematurely discontinue anticoagulant therapy (<90 days) are at an increased risk for death or recurrences. Methods We used the data from the RIETE (Registro Informatizado de Pacientes con Enfermedad TromboEmbólica) registry to compare the prognostic ability of five machine-learning (ML) models and logistic regression to identify patients at increased risk for the composite of fatal PE or recurrent venous thromboembolism (VTE) 30 days after discontinuation. ML models included decision tree, k-nearest neighbors algorithm, support vector machine, Ensemble, and neural network [NN]. A “full” model with 70 variables and a “reduced” model with 23 were analyzed. Model performance was assessed by confusion matrix metrics on the testing data for each model and a calibration plot. Results Among 34,447 patients with PE, 1,348 (3.9%) discontinued therapy prematurely. Fifty-one (3.8%) developed fatal PE or sudden death and 24 (1.8%) had nonfatal VTE recurrences within 30 days after discontinuation. ML-NN was the best method for identification of patients experiencing the composite endpoint, predicting the composite outcome with an area under receiver operating characteristic (ROC) curve of 0.96 (95% confidence interval [CI]: 0.95–0.98), using either 70 or 23 variables captured before discontinuation. Similar numbers were obtained for sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. The discrimination of logistic regression was inferior (area under ROC curve, 0.76 [95% CI: 0.70–0.81]). Calibration plots showed similar deviations from the perfect line for ML-NN and logistic regression. Conclusion The ML-NN method very well predicted the composite outcome after premature discontinuation of anticoagulation and outperformed traditional logistic regression. * A full list of the RIETE investigators is given in [ Supplementary Appendix A ] . Received: 03 November 2020 Accepted: 08 June 2021 Accepted Manuscript online: 09 June 2021 Article published online: 13 July 2021 © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

1 October 2014 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
JNJosé Antonio Nieto
José Antonio Nieto
TCTimoteo Cámara
Timoteo Cámara
ICIsabel Camacho
Isabel Camacho

1 December 2018 in American Heart Journal
Verified
Journal Article
Closed access
JNJosé Antonio Nieto
José Antonio Nieto
JVJulio A. Vicente
Julio A. Vicente
LPLuis M. Prieto
Luis M. Prieto
DJDavid Jiménez
David Jiménez
BBBehnood Bikdeli
Behnood Bikdeli
MMManuel Monreal
Manuel Monreal

1 May 2020 in Thrombosis Research
Verified
Journal Article
Closed access
JNJosé Antonio Nieto
José Antonio Nieto
DMDamian Mora
Damian Mora
BBBehnood Bikdeli
Behnood Bikdeli
MPMontserrat Pérez Pinar
Montserrat Pérez Pinar
RVReina Valle
Reina Valle
MMManuel Monreal
Manuel Monreal